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coined the term dementia praecox more than a century ago to describe
schizophrenia, he conceptualized this psychotic disorder as a progressive
dementing illness or a neurodegenerative disease (Kraepelin, 1971). De-
terioration was an integral part of Kraepelin's description and diagnosis:
“if no essential improvement intervenes, in at most 2 or 3 years after the
appearance of the more striking morbid phenomena, a state of weak-
mindedness will be developed, which usually changes only slowly and
insigniﬁcantly” (p. 210). Since then, it has been a common perspective
that the long-termoutcomeof chronic schizophrenia is dismal,with clin-
ical deterioration most often leading to a terminal demented state. This
negative view has continued to persist despite empirical evidence that
schizophrenia is a heterogeneous disorder and a number of patients
can experience more favorable outcomes. Manfred Bleuler, son of Eu-
gene Bleuler who ﬁrst introduced the term schizophrenia to rename
Kraepelin's dementia praecox, was perhaps the ﬁrst researcher to iden-
tify that remission could occur in schizophrenia over a period of time.
He presented a view that schizophrenia was not necessarily a progres-
sive condition, and that individual patients' coursemightmanifest differ-
ent outcomes, including remission. In his long-term follow-up, Bleuler
found that 20% of patients with schizophrenia remained stable and
were “cured” over a period of many years (Bleuler, 1983). Subsequent
studies byHarding in the 1980s and 1990s also challenged the prevailing
misconception of a progressively worsening clinical trajectory in schizo-
phrenia and emphasized instead the considerable heterogeneity in the
long-term outcome of this illness, with deteriorated states not being in-
evitable (Harding et al., 1987; Harding et al., 1992).
However, despite the publication of these facts and ﬁgures, the notion
still persists that schizophrenia is necessarily a lifelong illness – a life sen-
tence of sorts, and the nature of sustained remission is often questioned.
Our earlier study of aging in schizophrenia reported that 8% of middle-
aged and older adults living in the community, suffering from chronic
schizophrenia with duration of several decades, met strict research
criteria for sustained remission (Auslander and Jeste, 2004). These criteria
included “normal” psychosocial functioning as reported by others, no⁎ Corresponding author at: Sam and Rose Stein Institute for Research on Aging,
University of California San Diego, 9500 Gilman Drive #0664, La Jolla, CA 92093, United
States of America.
E-mail address: djeste@ucsd.edu (D.V. Jeste).
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0920-9964/© 2019 Elsevier B.V. All rights reserved.psychiatric hospitalization for at least previous ﬁve years, and either not
being on antipsychotic medications or not taking more than half of the
highest daily dose since enrollment. These ﬁnding indicated that
sustained remission could occur even in patients with very chronic ill-
ness. Predictors of sustained remission include social support, early initi-
ation of treatment, greater cognitive and/or personality reserve, and
having a partner or spouse. Interestingly, neither age nor duration of
treatment was predictors, suggesting that it is never too late to intervene
or hold the possibility of remission. Such observations offer hope and sug-
gest that remission rates could bemuch higher if peoplewith schizophre-
nia received optimal care, which includes not only pharmacological
treatment of psychiatric symptoms from an early stage but also general
medical care and psychosocial and vocational support and resources.
The article by (Lange et al. 2019) further builds on the growing area of
research suggesting that aging in schizophrenia is frequently associated
with a potential for lasting symptomatic remission. This study is an ex-
tension of the authors' previous work investigating the longitudinal
course of symptomatic remission in older patients with schizophrenia
over a 5-year period (Meesters et al., 2011). These Dutch researchers
found that the rate of remission substantially increased from 27.3% at
baseline to 49.4% at follow-up. Notably, 26% of patients converted from
non-remission to remission status over the follow-up period, with only
3.9% converting from remission to non-remission. Reduced positive
symptom severity and having a partner at baseline were signiﬁcant pre-
dictors of conversion to remission over the 5-year period. This is this ﬁrst
known longitudinal study of recovery and remission in older patients
with schizophrenia employing a catchment area-based design. The au-
thors appropriately acknowledged limitations of their investigation
such as a small sample size, somewhat biased sample, and a lack of infor-
mation about the life events or changes that might have occurred be-
tween the two assessments. At the same time, a noteworthy strength of
this study is its inclusion of both community-living and institutionalized
patients and of all patients regardless of the age of onset of the disorder.
These ﬁndings further support what has been reported in several
other studies that even older adults with schizophrenia have the capac-
ity to experience remission of symptoms and progress toward recovery.
There is an important distinction between the models of remission and
recovery in chronic mental illness compared to those for physical dis-
eases. Unlike some cancers, remission does not entail a cure or imply
that patients are free from the underlying etiopathology. Instead,
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Author's Personal Copyrecovery in schizophrenia should be conceptualized as the ability to live
ameaningful, satisfying, and hopeful life despite the limitations imposed
by symptoms, rather than resulting from elimination of symptoms
(Bellack, 2006). Advocacy organizations, especially theNational Alliance
on Mental Illness (NAMI) and the National Empowerment Center, have
been central to the recoverymovement in seriousmental illnesses. They
have argued that the nature of recoverymay be different from the tradi-
tional disease-oriented scientiﬁc-clinical concept centered on complete
disappearance of symptoms and return to premorbid levels of function.
This new perspective is consistent with improvement in mental health
in later life despite worsening physical health in the general population
as well as in people with serious physical illnesses, like cancer and HIV-
AIDS (Jeste, 2018). Of particular relevance to older patients with schizo-
phrenia, remission and recovery are akin to the deﬁnitions “successful
aging” based on subjectively experiencedwell-being rather on objective
presence and severity of physical illness. Aging in schizophrenia is asso-
ciated with a paradoxical clinical proﬁle of worse physical health but
improved psychosocial functioning, including decreased level of psy-
chotic symptoms, reduction in psychotic relapses requiring hospitaliza-
tion, and better self-management (Jeste et al., 2011). The better mental
health in later life centers on well-being, adaptation, attainment or
maintenance of goals, positive attitudes toward the self and future,
and social milestones and connectedness. Multi-component interven-
tions that include lifestyle and other behavioral interventions, in addi-
tion to pharmacotherapy, are critical in optimizing successful aging in
people with schizophrenia. Psychosocial interventions for schizophre-
nia have been shown to be associated with altered brain structure and
function. For instance, cognitive enhancement therapy led to signiﬁ-
cantly increased brain-derived neurotrophic factor (BDNF) in the
blood (Vinogradov et al., 2009), greater preservation of graymatter vol-
ume in the temporal lobes, and increased gray matter in the amygdala
onMRI (Eack et al., 2010). Thus, although the underlying pathophysiol-
ogy may continue to be present, these studies suggest that behavioral
interventions can produce neurobiological changes, suggesting a possi-
ble biological basis for improved functioning observed in schizophrenia
patients who achieve remission.
Where dowe go from here? Despite growing empirical evidence that
schizophrenia is heterogeneous in its presentation and course, a negative
view of schizophrenia still persists. To change this bias, we advocate for
positive psychiatry in conceptualizing schizophrenia and other serious
mental illnesses. Positive psychiatry focuses on the promotion of mental
health andwell-being through enhancement of positive psychosocial fac-
tors relevant tomental and physical illnesses (Jeste et al., 2017). Focusing
on the negative outcomes and disability associated with schizophrenia,
most research attention has been directed in the past toward reducing
psychopathology. However, mental health is characterized not only by
an absence of symptoms but also by the presence of mental well-being
and other positive outcomes, such as life satisfaction and happiness. Pos-
itive psychiatry offers an alternative and more empowering perspective
from which scientists and clinicians should approach treatment for
schizophrenia. Mental well-being and positive psychological traits can
be and are present in schizophrenia, if we look for them. Although pa-
tients with schizophrenia tend to have lower mean levels of resilience,
optimism, wisdom, happiness, and low perceived stress, there is consid-
erable heterogeneity among patients, with one-third having levels com-
parable to those in healthy comparison subjects (Edmonds et al., 2018;
Palmer et al., 2014). Furthermore, greater presence of such positive fac-
tors is signiﬁcantly associated with improved physical well-being and
even healthier levels of biomarkers of inﬂammation and insulin resis-
tance (Edmonds et al., 2018; Lee et al., 2018). These ﬁndings suggest
thatmentalwell-being should be a treatment goal in schizophrenia to op-
timize a likelihood of remission. Although individuals with schizophrenia
may report higher prevalence of adverse life events and generally worse
physical health, these positive psychological traits are potentially modiﬁ-
able and could promote both mental and physical well-being andpossibly curtail accelerated biological aging trajectories. Positive psychia-
try provides a light at the end of the tunnel and gives hope to patients,
their families, clinicians, and the public at large, thereby helping the pro-
cess of eliminating the stigma associated with serious mental illnesses.
Increasing the focus in mental healthcare on positive psychological fac-
tors such as resilience, optimism, hope, wisdom, and social support, is
critical for promoting overall wellness in people with schizophrenia. A
positive change in attitude about the chronicity of schizophrenia is neces-
sary among scientists and clinicians, which in turn will effect a similar
change among people with schizophrenia and their families. While we
wait for the biological means of curing and preventing schizophrenia,
we must strive to change the societal attitude toward persons with
schizophrenia and improve the rates of recovery in this long-neglected
group of people. A wise society is deﬁned by how it cares for its most
disenfranchised segments.
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